New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 24, 2012
08:04 EDTRPTPRaptor Pharma weakness may provide buying opporutnity, says Oppenheimer
After Raptor announced that the FDA had postponed its decision on approving Raptor's Procysbi for three months until April 30, 2013, Oppneheimer views the news as a short-term negative for the company but doesn't think it has any implication on the FDA's ultimate decision about Procysbi. The firm maintains an Outperform rating on Raptor.
News For RPTP From The Last 14 Days
Check below for free stories on RPTP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:58 EDTRPTPRaptor Pharma should be owned ahead of potential catalysts, says JMP Securities
JMP Securities believes that Raptor has a number of potentially transformative upcoming catalysts. The firm thinks that adoption of the company's Proscybi drug could be a number of times higher than current levels, and it thinks that data due to be released over the next several months could be transformative for the company. The firm reiterates a $33 price target and Outperform rating.
September 11, 2014
09:38 EDTRPTPRaptor Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use